MIRCETTE (desogestrel; ethinyl estradiol) by Teva is clinical pharmacology pharmacodynamics combined oral contraceptives act by suppression of gonadotropins. Approved for pregnancy in women. First approved in 1998.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
MIRCETTE is a combination oral contraceptive containing desogestrel (progestin) and ethinyl estradiol (estrogen). It prevents pregnancy by suppressing gonadotropins to inhibit ovulation, while also altering cervical mucus and endometrial tissue to reduce sperm entry and implantation likelihood. The active metabolite 3-keto-desogestrel provides high progestational activity with minimal androgenicity.
Product is in declining phase with minimal Part D utilization; expect downsizing of brand team and shift to generic/lifecycle management roles.
CLINICAL PHARMACOLOGY Pharmacodynamics Combined oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus, which increase the difficulty of sperm entry into the uterus,…
Worked on MIRCETTE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on MIRCETTE offers limited growth opportunity due to LOE-approaching lifecycle and minimal linked job postings (0 current positions). Career trajectory will likely involve transition from brand-building to lifecycle management, generic conversion support, or redeployment to growth-stage products within Teva's portfolio.